J
James A. Tumlin
Researcher at University of Tennessee
Publications - 40
Citations - 3289
James A. Tumlin is an academic researcher from University of Tennessee. The author has contributed to research in topics: Acute kidney injury & Renal replacement therapy. The author has an hindex of 26, co-authored 40 publications receiving 2591 citations. Previous affiliations of James A. Tumlin include University of Tennessee at Chattanooga.
Papers
More filters
Journal ArticleDOI
Angiotensin II for the Treatment of Vasodilatory Shock.
Ashish Khanna,Shane W. English,Xueyuan S. Wang,Kealy R. Ham,James A. Tumlin,Harold M. Szerlip,Laurence W. Busse,Laith Altaweel,Timothy E Albertson,Caleb Mackey,Michael T. McCurdy,David W. Boldt,Stefan N. Chock,Paul J Young,Kenneth Krell,Richard G. Wunderink,Marlies Ostermann,Raghavan Murugan,Michelle N. Gong,Rakshit Panwar,Johanna Hästbacka,Raphael Favory,Balasubramanian Venkatesh,B. Taylor Thompson,Rinaldo Bellomo,Jeffrey B. Jensen,Jeffrey B. Jensen,Stew Kroll,Lakhmir S. Chawla,George F. Tidmarsh,George F. Tidmarsh,George F. Tidmarsh,Adam M. Deane +32 more
TL;DR: Angiotensin II effectively increased blood pressure in patients with vasodilatory shock that did not respond to high doses of conventional vasopressors.
Journal ArticleDOI
Development and standardization of a furosemide stress test to predict the severity of acute kidney injury.
Lakhmir S. Chawla,Danielle Davison,Ermira Brasha-Mitchell,Jay L. Koyner,John M. Arthur,Andrew D. Shaw,James A. Tumlin,Sharon Trevino,Paul L. Kimmel,Michael G. Seneff +9 more
TL;DR: The FST in subjects with early AKI serves as a novel assessment of tubular function with robust predictive capacity to identify those patients with severe and progressive AKI.
Journal ArticleDOI
Incidence of Contrast-Induced Nephropathy after Contrast-Enhanced Computed Tomography in the Outpatient Setting
TL;DR: CIN occurs in >10% of patients who undergo CECT in the outpatient setting and is associated with a significant risk for severe renal failure and death.
Journal ArticleDOI
Furosemide Stress Test and Biomarkers for the Prediction of AKI Severity
Jay L. Koyner,Danielle Davison,Ermira Brasha-Mitchell,Divya M. Chalikonda,John M. Arthur,Andrew D. Shaw,James A. Tumlin,Sharon Trevino,Michael R. Bennett,Paul L. Kimmel,Michael G. Seneff,Lakhmir S. Chawla +11 more
TL;DR: Overall, in the setting of earlyAKI, FST urine output outperformed biochemical biomarkers for prediction of progressive AKI, need for RRT, and inpatient mortality, although further research is needed.
Journal ArticleDOI
A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis.
Brad H. Rovin,Neil Solomons,William F. Pendergraft,Mary Anne Dooley,James A. Tumlin,Juanita Romero-Diaz,Lidia Lysenko,Sandra V. Navarra,Robert B. Huizinga,Ihar Adzerikho,Elena Mikhailova,Natalya Mitkovskaya,Sergey Pimanov,Nikolay Soroka,Boris Iliev Bogov,Boriana Deliyska,Valentin Ikonomov,Eduard Tilkiyan,Ruth Almeida,Fernando Jimenez,Faud Teran,Irma Tchokhonelidze,Nino Tsiskarishvili,Maynor Herrera Mendez,Nilmo Noel Chavez Perez,Arturo Reyes Loaeza,Sergio Ramon Gutierrez Urena,Juanita Romero Diaz,Rodolfo Araiza Casillas,Magdalena Madero Rovalo,Stanislaw Niemczyk,Antoni Sokalski,Andrzej Wiecek,Marian Klinger,Olga V. Bugrova,Tatiana M. Chernykh,Tatiana R. Kameneva,Lidia Lysenko,Tatiana A. Raskina,Olga V. ReshEtko,Natalia N. Vezikova,Tatiana V. Kropotina,Adelya N. Maksudova,Vyacheslav Marasaev,Vladimir A. Dobronravov,Ivan Gordeev,Ashot M. EssAian,Alexey Frolov,Rosa Jelacic,Dragan Jovanovic,Branka Mitic,Gordana Pekovic,Milan Radovic,Goran Radunovic,Patricia Carreira,Federico Diaz Gonzalez,Xavier Fulladosa,Eduardo Ucar,Shamila De Silva,Chula Herath,Anura Hewageegana,Abdul Latiff Mohamed Nazar,A.W.M. Wazil,Iryna Dudar,Olga Godlevska,Svitlana Korneyeva,ViktoriIa Vasylets,Nataliya Sydor,Mykola Kolesnyk,Samir V. Parikh,Nancy J. Olsen,Ellen M. Ginzler,James A. Tumlin,Amit Saxena,Ramesh Saxena,Richard A. Lafayette,William Franklin Pendergraft,Amber S. Podoll,Annie A. Arrey-Mensah,Michael Bubb,Jennifer Grossman,Alejandro I. Oporta,Alireza Nami,Md. Mujibur Rahman,Syed Atiqul Haq,Tak Mao Chan,Mok Mo Yin Temy,Harold Michael P. Gomez,James Bermas,Bernadette Heizel Reyes,Llewellyn T. Hao,Linda Charmaine Roberto,Eric Amante,Allan E. Lanzon,Jung-Yoon Choe,Tae Young Kang,Yon Su Kim,Seung-Geun Lee,Ji Soo Lee,Jason Choo Chon Jun,Archana Vasudevan,Shue-Fen Luo,Tien-Tsai Cheng,Bancha Satirapoj,Kajohnsak Noppakun +104 more
TL;DR: The AURA-LV study suggests that the addition of low-dose voclosporin to mycophenolate mofetil and corticosteroids for induction therapy of active LN results in a superior renal response compared to myCophenolatemofetIL and cortICosteroids alone, but higher rates of adverse events including death were observed.